TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33160931

Group type: EXPERIMENTAL
Intervention: Skin patch test (SPT) with sodium lauryl sulfate, cocamidopropyl betaine, propylene glycol, aluminum chloride hexahydrate, menthol, triclosan, and titanium dioxide
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Skin patch test (SPT)
Number of subjects: 63
Study: 33726797

Group type: EXPERIMENTAL
Intervention: Both prenatal counselling and postnatal support
Number of subjects: 9124

Group type: EXPERIMENTAL
Intervention: Only postnatal support
Number of subjects: 9124

Group type: EXPERIMENTAL
Intervention: Only prenatal counselling
Number of subjects: 9124

Group type: EXPERIMENTAL
Intervention: Both prenatal counselling and postnatal support at public health facilities
Number of subjects: 9124

Group type: EXPERIMENTAL
Intervention: Both prenatal counselling and postnatal support at private health facilities
Number of subjects: 9124

Group type: EXPERIMENTAL
Intervention: Both prenatal counselling and postnatal support at home
Number of subjects: 9124
Study: 34264700

Group type: EXPERIMENTAL
Intervention: Perceived Burdensomeness (PB)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Suicidal Ideation (SI)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Thwarted Belongingness (TB)
Number of subjects: 129
Study: 33046478

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team‐based medication optimisation
Number of subjects: 500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study: 33319756

Group type: EXPERIMENTAL
Intervention: Combined financial incentives and behavioral weight management
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 124
Study: 35727349

Group type: EXPERIMENTAL
Intervention: 8 days of antibiotic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 days of antibiotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32366329

Group type: EXPERIMENTAL
Intervention: MBSR training (Intervention Group 1)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: MBSR training combined with an additional organisational health intervention (Intervention Group 2)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Waiting list group (Control Group)
Number of subjects: 66
Study: 33879219

Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) before medical consultation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) - medical consultation alone
Number of subjects: 128
Study: 32220283

Group type: EXPERIMENTAL
Intervention: Butantan-DV
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: TV003
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 34083331

Group type: EXPERIMENTAL
Intervention: Targeted therapy with corresponding targeted drugs for patients with actionable alterations.
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor treatment with sintilimab for patients without actionable alterations.
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Combination treatment with sintilimab or atezolizumab after resistance to vemurafenib, niraparib, and palbociclib.
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Single-agent immunotherapy (sintilimab) in the single-agent immunotherapy group.
Number of subjects: 770
Study: 33082187

Group type: EXPERIMENTAL
Intervention: External inspections of sepsis detection and treatment
Number of subjects: 7407
Study: 33449867

Group type: EXPERIMENTAL
Intervention: Combined therapy of r-IPL and fractional CO2 laser
Number of subjects: 22

Group type: COMPARATOR
Intervention: Therapeutic standard dose of the fractional CO2 laser
Number of subjects: 22
Study: 32011809

Group type: EXPERIMENTAL
Intervention: Warmed humidified carbon dioxide (WHCO2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard insufflation)
Number of subjects: 40
Study: 35291025

Group type: EXPERIMENTAL
Intervention: Individualised STOPP/START-based medication optimisation recommendations discussed with patients and physicians
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Individualised STOPP/START-based medication optimisation recommendations
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Factors associated with higher agreement
Number of subjects: 139
Study: 33441093

Group type: EXPERIMENTAL
Intervention: Metacognitive Training (MCT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Community-based rehabilitation (CBR)
Number of subjects: 124
Study: 34091062

Group type: EXPERIMENTAL
Intervention: Nurse facilitator trained to support, model, and teach communication strategies for 3 months in ICU and beyond.
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Nurse facilitator intervention
Number of subjects: 776

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 776
Study: 32698540

Group type: EXPERIMENTAL
Intervention: Dynamic Food Labels with Real-Time Feedback (DFLF)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No-label control
Number of subjects: 125
Study: 35124475

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 56

Group type: COMPARATOR
Intervention: Acupuncture and Electroacupuncture
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Salivary cortisol levels (morning)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Salivary cortisol levels (night)
Number of subjects: 56
Study: 33742233

Group type: EXPERIMENTAL
Intervention: Total Margin-Controlled Excision (TMCE)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard Excision (SE)
Number of subjects: 148
Study: 32914161

Group type: COMPARATOR
Intervention: Dexmedetomidine 0.2 μg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl 0.2 μg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Bupivacaine 0.5% 2 mL)
Number of subjects: 60
Study: 36215947

Group type: EXPERIMENTAL
Intervention: Trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821
Number of subjects: 136

Group type: COMPARATOR
Intervention: OPT-821 alone (adjuvant only)
Number of subjects: 136
Study: 33938673

Group type: EXPERIMENTAL
Intervention: Updated SedLine® algorithm (v.2000)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Old SedLine® algorithm (v.1203)
Number of subjects: 33
Study: 32609805

Group type: EXPERIMENTAL
Intervention: The Safety Class, an abuse prevention group program
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 170
Study: 35414106

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 476

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg (control group)
Number of subjects: 476
Study: 34011047

Group type: EXPERIMENTAL
Intervention: 1 layer (120-150 μm) of allogeneic lamellar corneal tissue as the graft (Group A)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 2 layers of lamellar corneal tissue from one donor (Group B)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: 3 layers of lamellar corneal tissue from 2 donors (Group C)
Number of subjects: 328
Study: 32798261

Group type: EXPERIMENTAL
Intervention: 100 mg saffron daily for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 35125131

Group type: EXPERIMENTAL
Intervention: GtACH programme
Number of subjects: 1657

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1657
Study: 34154669

Group type: EXPERIMENTAL
Intervention: Willingness to engage in romantic love and marital relationships with persons with disabilities
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Fear of reaction from family members
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Sex of respondents
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Raised-up area of respondents
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Age of respondents
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Presence of a person with disability in the family
Number of subjects: 403
Study: 33213066

Group type: EXPERIMENTAL
Intervention: Seawater Pizza (SWP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard traditional Pizza (StP)
Number of subjects: 12
Study: 34327187

Group type: EXPERIMENTAL
Intervention: Couple-based collaborative management model (CCMM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patient-only control arm
Number of subjects: 36
Study: 32133688

Group type: EXPERIMENTAL
Intervention: Open cohort sampling structure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed cohort sampling structure
Number of subjects: 0
Study: 35653744

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy-trauma (IPT-T)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Clinic psychotherapy (CP)
Number of subjects: 162
Study: 33049235

Group type: EXPERIMENTAL
Intervention: VUR/BBD
Number of subjects: 7

Group type: COMPARATOR
Intervention: VUR
Number of subjects: 7
Study: 34156181

Group type: EXPERIMENTAL
Intervention: WBV (whole-body vibration) before RSA and during recovery between sets
Number of subjects: 11

Group type: COMPARATOR
Intervention: WBV-without (warm-up and passive recovery)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: WBV (whole-body vibration) during recovery
Number of subjects: 11
Study: 33300682

Group type: EXPERIMENTAL
Intervention: Enhanced Homestead Food Production programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35279213

Group type: EXPERIMENTAL
Intervention: Rusk-like biscuit powder with hen's egg (HE), cow’s milk (CM), peanut (PN), and hazelnut (HN) (initially approximately 2 mg of each food protein) for 6–8 months.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo group receiving rusk-like biscuit powder without HE, CM, PN, and HN on a daily basis.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rusk-like biscuit powder with HE, CM, PN, and HN.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo group receiving rusk-like biscuit powder without HE, CM, PN, and HN.
Number of subjects: 150
Study: 33822910

Group type: EXPERIMENTAL
Intervention: Genetically predicted short sleep duration (≤6 h)
Number of subjects: 404044

Group type: EXPERIMENTAL
Intervention: Genetically predicted long sleep duration (≥9 h)
Number of subjects: 404044
Study: 34161616

Group type: EXPERIMENTAL
Intervention: Eliglustat therapy
Number of subjects: 40
Study: 32104685

Group type: EXPERIMENTAL
Intervention: SNP rs10403848
Number of subjects: 0

Group type: COMPARATOR
Intervention: SNP rs2043211
Number of subjects: 0
Study: 36001700

Group type: EXPERIMENTAL
Intervention: Low-frequency contact ultrasonic debridement (LFCUD) plus polyhexamethylene biguanide (PHMB)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-frequency contact ultrasonic debridement (LFCUD) plus polyhexamethylene biguanidine (PHMB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (LFCUD with non-antimicrobial products)
Number of subjects: 50
Study: 33639045

Group type: EXPERIMENTAL
Intervention: Vitamin K2 (100 mcg menaquinone-7) and vitamin D3 (10 mcg calcitriol)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Vitamin K2 and vitamin D3
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 29
Study: 32197805

Group type: EXPERIMENTAL
Intervention: Video-based rehabilitation (VBR) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physiotherapist-supervised rehabilitation (PSR) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: PSR group
Number of subjects: 30
Study: 36190994

Group type: EXPERIMENTAL
Intervention: Dexamethasone 6 mg daily
Number of subjects: 107

Group type: COMPARATOR
Intervention: Dexamethasone 20 mg daily
Number of subjects: 107
Study: 34275095

Group type: EXPERIMENTAL
Intervention: Derivation cohort with pericarditis score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validation group with pericarditis score
Number of subjects: 0
Study: 32909921

Group type: EXPERIMENTAL
Intervention: CPAP + OA (oral airway open)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CPAP + OA (oral airway closed)
Number of subjects: 16

Group type: COMPARATOR
Intervention: CPAP only
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CPAP + OA (oral airway open) and CPAP + OA (oral airway closed)
Number of subjects: 16
Study: 35477531

Group type: EXPERIMENTAL
Intervention: Modified Buzhong Yiqi decoction (MBYD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33004230

Group type: EXPERIMENTAL
Intervention: Higher log transformed urinary sodium
Number of subjects: 446237
Study: 32227713

Group type: EXPERIMENTAL
Intervention: Yun's optimized pelvic floor training (OPFT) therapy for 6 weeks followed by 6 weeks of traditional pelvic floor muscle exercises (PFME)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional pelvic floor muscle exercises (PFME) for 6 weeks followed by 6 weeks of Yun's OPFT therapy
Number of subjects: 80
Study: 35026375

Group type: EXPERIMENTAL
Intervention: Favipiravir 1800 mg by mouth twice daily on day 1 followed by 800 mg twice daily for 5 to 7 days
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 231
Study: 34198004

Group type: EXPERIMENTAL
Intervention: Karate intervention (Karate Mind and Movement program) for 1 year
Number of subjects: 721

Group type: COMPARATOR
Intervention: Control group (habitual physical education lessons)
Number of subjects: 721
Study: 35444795

Group type: EXPERIMENTAL
Intervention: Pen
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: £5 cash
Number of subjects: 818

Group type: COMPARATOR
Intervention: Control (no pen)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Control (no £5)
Number of subjects: 818
Study: 35606820

Group type: EXPERIMENTAL
Intervention: baricitinib 4mg/day
Number of subjects: 83

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 83
Study: 32250328

Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilization (DNS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional neurodevelopmental treatment (NDT)
Number of subjects: 31
Study: 369727056

Group type: EXPERIMENTAL
Intervention: Dietary counselling with probiotics
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 256
Study: 35342931

Group type: EXPERIMENTAL
Intervention: Standard treatment + aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 34514764

Group type: EXPERIMENTAL
Intervention: Combination program including smartphone nutrition education, physical activity (aerobics exercise for 45 minutes three times per week), and cognitive behavioral therapy (CBT) sessions (8 sessions designed for children)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Traditional education method (lectures by a nutritionist regarding weight management)
Number of subjects: 62
Study: 34548479

Group type: EXPERIMENTAL
Intervention: Eribulin + Pembrolizumab
Number of subjects: 88

Group type: COMPARATOR
Intervention: Eribulin
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ICI-related toxicity
Number of subjects: 88
Study: 35045374

Group type: EXPERIMENTAL
Intervention: Motor skill training
Number of subjects: 154

Group type: COMPARATOR
Intervention: Strength and flexibility exercise
Number of subjects: 154
Study: 33164922

Group type: EXPERIMENTAL
Intervention: Educational program with evidence-based messages and web-based interventions (videos and classes) delivered by a multidisciplinary panel of experts.
Number of subjects: 32
Study: 32300382

Group type: EXPERIMENTAL
Intervention: Chemical blockage of celiac ganglions by ethanol injection
Number of subjects: 118

Group type: COMPARATOR
Intervention: Non-injected control group
Number of subjects: 118
Study: 35050348

Group type: EXPERIMENTAL
Intervention: Single agent nivolumab
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combination nivolumab and ipilimumab
Number of subjects: 29
Study: 33938676

Group type: EXPERIMENTAL
Intervention: Glidescope videolaryngoscope
Number of subjects: 14

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope
Number of subjects: 14
Study: 35181470

Group type: EXPERIMENTAL
Intervention: MRI-based radiomics models integrating contours with clinical data
Number of subjects: 110

Group type: COMPARATOR
Intervention: Traditional TNM staging and clinical data
Number of subjects: 110
Study: 32676853

Group type: EXPERIMENTAL
Intervention: Chemotherapy for GI malignancy
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Pre-chemotherapy screening
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Investigations for chemotherapy-induced symptoms
Number of subjects: 241
Study: 33170838

Group type: EXPERIMENTAL
Intervention: Clinical risk score (0 to 10) based on age, sex, HIV (2 points), diabetes, number of classical TB symptoms (1 point each), and >14‐day symptom duration.
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: De novo Ugandan model with similar characteristics to South African model.
Number of subjects: 701
Study: 36428060

Group type: EXPERIMENTAL
Intervention: Online laughter therapy (twice weekly for four weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study: 33715056

Group type: EXPERIMENTAL
Intervention: Cement applied on bone surfaces (group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cement applied on implant surfaces (group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cement applied on both bone and implant surfaces (group 3)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall comparison of cement application techniques
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cement intrusion in tibia
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cement amount correlation
Number of subjects: 90
Study: 33070132

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 84
Study: 36460701

Group type: EXPERIMENTAL
Intervention: Intervention aimed at reducing and breaking up sedentary time (InPact, ISRCTN28668090)
Number of subjects: 0
Study: 32307227

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) after paramedical care
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) after secondary care
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) after primary care
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Visiting a physiotherapist
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Use of braces and/or tape during sport after paramedical care
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Use of braces and/or tape during sport after primary care
Number of subjects: 705

Group type: COMPARATOR
Intervention: Use of braces and/or tape during sport without any care
Number of subjects: 705
Study: 35812412

Group type: EXPERIMENTAL
Intervention: WIBP-CorV vaccine (2.5, 5.0, and 10.0μg/dose)
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: WIBP-CorV vaccine
Number of subjects: 816

Group type: COMPARATOR
Intervention: Alum-only control
Number of subjects: 816
Study: 35102638

Group type: EXPERIMENTAL
Intervention: PFCs cemented with GIC
Number of subjects: 120

Group type: COMPARATOR
Intervention: PZCs
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PFCs cemented with RMGIC
Number of subjects: 120

Group type: COMPARATOR
Intervention: PZCs cemented with GIC
Number of subjects: 120

Group type: COMPARATOR
Intervention: PZCs cemented with RMGIC
Number of subjects: 120
Study: 36349727

Group type: EXPERIMENTAL
Intervention: Monetary incentives provided to community-based volunteers
Number of subjects: 0
Study: 34111067

Group type: EXPERIMENTAL
Intervention: Blended learning (BL)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Face-to-face teaching (f2f)
Number of subjects: 59
Study: 32620810

Group type: EXPERIMENTAL
Intervention: Stabilization splint (SS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo splint (PS)
Number of subjects: 34
Study: 35393915

Group type: EXPERIMENTAL
Intervention: Digital modeling and 3D printing of titanium mesh for thyroid cartilage reconstruction
Number of subjects: 44

Group type: COMPARATOR
Intervention: Modified crico-hyoido-epiglottopexy (CHEP)
Number of subjects: 44
Study: 33433260

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual occupational therapy exercises (Control)
Number of subjects: 71
Study: 35246387

Group type: EXPERIMENTAL
Intervention: somofilcon A (SiHy)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: etafilcon A (Hy)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combined analysis
Number of subjects: 55
Study: 32998926

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg subcutaneous weekly until week 4, then at week 8; escalated to 300 mg subcutaneous every 4 weeks for non-responders at week 12; switched to adalimumab biosimilar 40 mg subcutaneous every 2 weeks for non-responders at week 24.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care treatment at the discretion of the physician.
Number of subjects: 0
Study: 35043539

Group type: EXPERIMENTAL
Intervention: BioFreedom stent (BF-BES)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Orsiro stent (O-SES)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Both stent types
Number of subjects: 607
Study: 32826001

Group type: EXPERIMENTAL
Intervention: Breathing retraining and four weekly manual therapy sessions (immediate start)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Breathing retraining and four weekly manual therapy sessions (delayed start)
Number of subjects: 18
Study: 616743252

Group type: EXPERIMENTAL
Intervention: Mother support groups (MSGs) established in 14 clinics, meeting every 2 weeks; Coordinated by volunteer HIV-positive mothers providing health education and reminders via cell phone.
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control arm (no MSGs) in 13 clinics.
Number of subjects: 348

Group type: COMPARATOR
Intervention: Overall retention and program outcomes in intervention arm versus control arm.
Number of subjects: 348
Study: 35773713

Group type: EXPERIMENTAL
Intervention: Biosimilar denosumab (Arylia)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Reference denosumab (Prolia®)
Number of subjects: 190
Study: 33794854

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional intermedullary (IM) guides
Number of subjects: 29
Study: 32277816

Group type: EXPERIMENTAL
Intervention: EnrichrBot
Number of subjects: 0